Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis
Phase Ia/Ib Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis
Sponsor: Alexion Pharmaceuticals, Inc.
A PHASE1 clinical study on AL Amyloidosis, this trial is completed. The trial is conducted by Alexion Pharmaceuticals, Inc. and has accumulated 10 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Mar 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Mar 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
▶ Show 5 earlier versions
-
Feb 2018 — Jun 2018 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Aug 2017 — Feb 2018 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jun 2017 — Aug 2017 [monthly]
Recruiting PHASE1
-
Feb 2017 — Jun 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Oct 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Alexion Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .